SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring

The COVID-19 pandemic is an ongoing global challenge for public health systems. Ultrasensitive and early identification of infection is critical in preventing widespread COVID-19 infection by presymptomatic and asymptomatic individuals, especially in the community and in-home settings. We demonstrat...

Full description

Saved in:
Bibliographic Details
Published in:Matter 2020-12, Vol.3 (6), p.1981-1998
Main Authors: Torrente-Rodríguez, Rebeca M., Lukas, Heather, Tu, Jiaobing, Min, Jihong, Yang, Yiran, Xu, Changhao, Rossiter, Harry B., Gao, Wei
Format: Article
Language:English
Subjects:
antibody
antigen
biosensors
C-reactive protein
COVID-19
electrochemical
graphene
SARS-CoV-2
Telemedicine
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The COVID-19 pandemic is an ongoing global challenge for public health systems. Ultrasensitive and early identification of infection is critical in preventing widespread COVID-19 infection by presymptomatic and asymptomatic individuals, especially in the community and in-home settings. We demonstrate a multiplexed, portable, wireless electrochemical platform for ultra-rapid detection of COVID-19: the SARS-CoV-2 RapidPlex. It detects viral antigen nucleocapsid protein, IgM and IgG antibodies, as well as the inflammatory biomarker C-reactive protein, based on our mass-producible laser-engraved graphene electrodes. We demonstrate ultrasensitive, highly selective, and rapid electrochemical detection in the physiologically relevant ranges. We successfully evaluated the applicability of our SARS-CoV-2 RapidPlex platform with COVID-19-positive and COVID-19-negative blood and saliva samples. Based on this pilot study, our multiplexed immunosensor platform may allow for high-frequency at-home testing for COVID-19 telemedicine diagnosis and monitoring. [Display omitted] •Multiplexed detection of SARS-CoV-2 antigen, antibodies, and C-reactive protein•Low-cost and mass manufacturable platform using laser-engraved graphene•Wireless telemedicine sensing platform with rapid sample-to-answer turnaround•Successful device evaluation in both COVID-19 patient blood and saliva samples The need for widespread testing to control the spread of COVID-19 has faced challenges due to testing backlogs, limited access to required equipment, and inaccurate assay results. To address this, we propose an ultrasensitive and low-cost telemedicine platform, the SARS-CoV-2 RapidPlex, based on target-specific immunoassays built off laser-engraved graphene for rapid and remote assessment of COVID-19 biomarkers (i.e., nucleocapsid protein, anti-spike protein IgG and IgM, and C-reactive protein). Multiplex sensing of these targets provides information on three key aspects of COVID-19 disease: viral infection, immune response, and disease severity. We successfully demonstrated the platform's applicability using COVID-19-positive and COVID-19-negative serum and saliva samples. The SARS-CoV-2 RapidPlex has the potential to quickly and effectively triage patients and track infection progression, allowing for the clear identification of individuals who are infectious, vulnerable, and/or immune. The SARS-CoV-2 RapidPlex is developed on the basis of laser-engraved graphene immunosensors to electrochemica
ISSN:2590-2385
2590-2393
2590-2385
DOI:10.1016/j.matt.2020.09.027